目的 分析蘇州九龍醫(yī)院2014-2018年口服抗高血壓藥物的使用情況及變化趨勢，為臨床合理用藥及藥品管理提供依據(jù)。方法 運用描述性統(tǒng)計分析方法，對2014-2018年蘇州九龍醫(yī)院口服抗高血壓藥物的品種結(jié)構(gòu)、銷售金額、用藥頻度（DDDs）、限定日費用（DDC）和排序比（B/A）等進行回顧性統(tǒng)計分析。結(jié)果 口服抗高血壓藥物共29個通用名、42個品規(guī)，均為蘇州市醫(yī)保品種，其中屬于2018版國家基本藥物目錄的共12個通用名、17個品規(guī)；不同年份口服抗高血壓藥物的品種略有差異；5大類品種年度使用金額及基藥占比均呈先增后降趨勢，不同品種年度金額占比較為穩(wěn)定，單片復(fù)方制劑占比最高，ACEI占比最低；不同年度使用金額與頻率排名前10位的品種較為集中；不同年度DDC最高的為2017年，最低的為2018年；B/A<1的品規(guī)數(shù)占比最高。結(jié)論 2014-2018年蘇州九龍醫(yī)院口服抗高血壓藥物及基本藥物品種的使用金額、使用頻率的排序與占比結(jié)構(gòu)較穩(wěn)定，隨著藥品新標降價政策的實施，使用金額與日均費用在2018年均有明顯的下降；不足之處在于價位較高藥品的使用占比較高，臨床藥師應(yīng)協(xié)助臨床醫(yī)師選擇價格適中，性價比相對高的藥物，更好的減輕患者的經(jīng)濟負擔(dān)。

Objective To analyze the use and trend of oral antihypertensive drugs in Suzhou Kowloon Hospital from 2014 to 2018, and provide evidence for clinical rational drug use and drug management. Methods Descriptive statistical analysis was used to retrospectively analyze the variety structure, sales amount, DDDs, DDC, and B/A of oral antihypertensive drugs in Suzhou Kowloon Hospital from 2014 to 2018. Results There were 29 generic names and 42 product specifications for oral antihypertensive drugs, all of which belong to Suzhou medical insurance varieties. Among them, there were 12 generic names and 17 product specifications belonging to the 2018 edition of the national essential drug catalogue. Varieties of oral antihypertensive drugs varied slightly in different years. The annual use amount and the proportion of base drugs in the five major categories showed a trend of increasing first and then decreasing. The annual amount of different varieties was stable, and the single-chip compound preparation accounted for the highest proportion, and ACEI with the lowest ratio. The top 10 varieties in different annual use amount and frequency were concentrated. The highest annual DDC was in 2017, and the lowest was in 2018. B/A <1 had the highest proportion of products. Conclusion The order and proportion of sum and DDDs of medicines for hypertension in Suzhou Kowloon Hospital from 2014 to 2018 are relatively stable. Consumption sum and DDC have obviously decreased in 2018, which is related to the implementation of the new drug price reduction policy. The disadvantage lies in the high proportion of drugs used in higher prices. Clinical pharmacists should assist clinicians in choosing medicines with moderate prices and relatively high cost-effectiveness, so as to better alleviate the financial burden of patients.

R972